NCT02978482 - A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

January 28, 2018

Study Completion Date

November 26, 2020

Conditions

Advanced Malignancy

Interventions

DRUG

durvalumab

durvalumab (MEDI4736) 20mg/kg via IV infusion every 4 weeks until confirmed disease progression or unacceptable toxicity

DRUG

tremelimumab + durvalumab

20 mg/kg durvalumab (MEDI4736) via IV infusion q4w and 1 mg/kg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 20 mg/kg durvalumab (MEDI4736) q4w starting on Week 16 for up to confirmed disease progression

Trial Locations (2)

130000

Research Site, Changchun

130012

Research Site, Changchun